Amanda is a health economist with expertise in economic evaluation and reimbursement, real–world evidence, and analysis of critical health policy issues. She is team leader for OHE’s Economics of Innovation theme, and outside of OHE holds a Visiting Lecturer position at UCL and is a member of ISPOR’s Health Science Policy Council.

Amanda’s current research interests include novel value–based payment mechanisms for pharmaceuticals, criteria for economic evaluation, and the interaction between HTA policy and optimal R&D decisions by industry. In particular, she is interested in how innovation in drug development calls for innovation in reimbursement and has worked on this in the context multi–indication therapies, precision
medicine and gene therapies, among others. She is passionate about developing a research agenda for how real–world evidence can change the way health care technologies are developed and adopted.